December 14, 2016
J&J shareholding in Biocartis decreases
Johnson&Johnson has decreased its shareholding in Biocartis, the Belgian drugmaker said on Wednesday. In a disclosure of a transparency notification,…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
December 14, 2016
Genticel: two year trial of HPV16/18 immunotherapeutic candidate fails
Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), has…
December 14, 2016
Sphere Medical launches next generation analyser, Proxima 4
Sphere Medical Holding, an innovative point-of-care monitoring and diagnostic devices company, has announced the launch of Proxima 4 in Europe.
December 14, 2016
FDA welcomes Obama signing Cures Act
Barack Obama has in his last days of presidency signed into law the 21st Century Cures Act, which is going…
December 13, 2016
Eli Lilly cuts insulin prices
Eli Lilly has announced that people who use Lilly insulin will be able to access discounted prices for their purchases…
December 13, 2016
GSK substitutes Pricewaterhouse with Delloite
GSK has announced on Tuesday that it intends to appoint Deloitte LLP (“Deloitte”) as its auditor with effect from the…
December 13, 2016
Pharnext: New approach in the treatment of Alzheimer’s disease
A French biopharmaceutical company focused on neurodegenerative diseases Pharnext, said that testing of a Pleodrug being developed for the treatment of…
December 13, 2016
FDA grants priority review status for AstraZeneca’s bladder cancer drug durvalumab
AstraZeneca’s application (BLA) for durvalumab for BLA in bladder cancer was accepted by the FDA. The PD-L1 human monoclonal antibody…
December 13, 2016
OptiBiotix’s SlimBiome technology for food and OTC products in Asian market
OptiBiotix Health has entered into a joint development agreement with a multinational for the development of food and Over The Counter…
December 13, 2016
4D pharma’s Blautix for Irritable Bowel Syndrome shows positive impact
4D Pharma’s Blautix, a single strain live biotherapeutic for the treatment of chronic abdomen disorder, Irritable Bowel Syndrome (IBS), has…